– USA, PA – Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the appointment of Leo Groothuis to its board of directors, filling the vacancy created by Michael Goettler in April.
“We are extremely pleased to welcome Leo Groothuis, a recognized top international executive to the Viatris board. We believe his proven strategic, corporate governance and capital markets experience should serve as a tremendous asset for Viatris, as we continue to look for ways to build and unlock value for our shareholders,” said Executive Chairman, Bob Coury.
About Leo Groothuis
Leo Groothuis has significant international experience and serves as General Counsel of HAL Investments, the Dutch investment subsidiary of HAL Holding N.V., a global investment company listed on the Amsterdam stock exchange focused on increasing shareholder value. In addition to his strategic, financial, and governance focus, he has also been actively involved in the development and execution of HAL Investments’ ESG strategy.
Throughout his career, Leo Groothuis has been a trusted C-suite and board advisor to some of the largest companies in both Europe and the U.S. Before his role at HAL Investments, he served as practice leader at NautaDutilh, an international law firm, where he guided numerous multi-national companies on significant and complex transactions. As a result, he is recognized as a top lawyer and thought leader in corporate governance, capital markets, and M&A.
About Viatris
Viatris Inc. is a global healthcare company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions, and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway. Formed in November 2020, Viatris brings together scientific, manufacturing, and distribution expertise with proven regulatory, medical, and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris’ portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, and various over-the-counter consumer products. With over 38,000 colleagues globally, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai, and Hyderabad, India.
For more information: https://www.viatris.com/en
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.